912762-85-7

Usage

Uses

Used in Pharmaceutical Industry:
[2-AMINO-2-(3-METHOXY-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients. Its role in drug development is crucial for creating new medications that can address a range of health conditions.
Used in Organic Chemistry and Chemical Research:
[2-AMINO-2-(3-METHOXY-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER may also find applications in the field of organic chemistry, where it can be utilized in various chemical reactions and processes. Its use in research settings can contribute to the advancement of chemical knowledge and the development of innovative chemical processes or products.

InChI:InChI=1/C14H22N2O3/c1-14(2,3)19-13(17)16-9-12(15)10-6-5-7-11(8-10)18-4/h5-8,12H,9,15H2,1-4H3,(H,16,17)

Upstream product

• 24037-72-7 2-amino-1-(3-methoxyphenyl)ethan-1-one hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 912762-53-9 C₁₄H₂₀N₂O₄ 
• 912762-33-5 tert-butyl (2-(3-methoxyphenyl)-2-oxoethyl)carbamate 
• 189506-47-6 2-amino-1-(3-methoxyphenyl)ethan-1-one 
• 5000-65-7 2-bromo-3'-methoxyacetophenone 

Relevant academic research and scientific papers

BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.

ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS

The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the act